We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

68 hedge funds and large institutions have $235M invested in Prelude Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,500% more call options, than puts

Call options by funds: $1.52M | Put options by funds: $20K

9% less funds holding

Funds holding: 75 → 68 (-7)

24% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 25

26.6% less ownership

Funds ownership: 98.22% → 71.61% (-27%)

37% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 19

46% less capital invested

Capital invested by funds: $438M → $235M (-$202M)

Holders
68
Holders Change
-7
Holders Change %
-9.33%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
19
Reduced
25
Closed
19
Calls
$1.52M
Puts
$20K
Net Calls
+$1.5M
Net Calls Change
+$1.47M

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$8.31M
2
BlackRock
BlackRock
New York
+$1.42M
3
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
+$560K
4
Bank of America
Bank of America
North Carolina
+$519K
5
IA
IndexIQ Advisors
New York
+$519K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.19M
2
Millennium Management
Millennium Management
New York
-$3.7M
3
Morgan Stanley
Morgan Stanley
New York
-$2.74M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.62M
5
CSS
Cubist Systematic Strategies
Connecticut
-$1.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$277K -$797K -87,100 -68%
Millennium Management
27
Millennium Management
New York
$271K -$3.7M -404,800 -91%
Manulife (Manufacturers Life Insurance)
28
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$238K +$313K +34,267 New
Squarepoint
29
Squarepoint
New York
$216K -$159K -17,333 -36%
Swiss National Bank
30
Swiss National Bank
Switzerland
$205K +$20.1K +2,200 +8%
TD Asset Management
31
TD Asset Management
Ontario, Canada
$196K – – –
OQS
32
Occudo Quantitative Strategies
Florida
$167K +$26K +2,845 +13%
Goldman Sachs
33
Goldman Sachs
New York
$166K -$816K -89,245 -79%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$163K +$216K +23,611 New
GCP
35
GSA Capital Partners
United Kingdom
$160K +$212K +23,201 New
AllianceBernstein
36
AllianceBernstein
Tennessee
$148K -$18K -1,968 -8%
Commonwealth Equity Services
37
Commonwealth Equity Services
Massachusetts
$141K -$21.6K -2,365 -10%
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$106K -$10.6K -1,154 -7%
VEA
39
Virtus ETF Advisers
New York
$90K -$7.01K -767 -6%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$81K -$249K -27,271 -70%
CC
41
Corton Capital
Ontario, Canada
$75K +$99.9K +10,918 New
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$69K +$91.9K +10,050 New
JP Morgan Chase
43
JP Morgan Chase
New York
$64K +$18.7K +2,040 +28%
Ensign Peak Advisors
44
Ensign Peak Advisors
Utah
$56K – – –
Deutsche Bank
45
Deutsche Bank
Germany
$43K -$6.4K -700 -10%
Barclays
46
Barclays
United Kingdom
$40K +$53.8K +5,877 New
AIG
47
American International Group
New York
$37K -$3.46K -378 -7%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$34K -$37.5K -4,100 -45%
Legal & General Group
49
Legal & General Group
United Kingdom
$27K – – –
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$22K -$15.2K -1,666 -34%
1
2
3 4

PRLD Hedge Fund Activity: Q1 2022 in Review

68 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2022, worth a combined $235M — down 46% from $438M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PRLD and 12 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 19 added.

The largest buyer was UBS AM, adding an estimated $8.31M. The largest seller was Fidelity Investments, cutting an estimated $5.19M.

  • 68 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2022, down from 75 in Q4 2021.
  • Funds reported $235M of Prelude Therapeutics stock for Q1 2022, down 46% quarter-over-quarter.
  • 12 funds opened new Prelude Therapeutics positions in Q1 2022 and 19 closed out, a net change of -7 holders.
  • The largest Prelude Therapeutics buyer in Q1 2022 was UBS AM, an estimated $8.31M added.
  • The largest Prelude Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $5.19M sold.

Based on aggregated 13F filings for Q1 2022.